Loading clinical trials...
Loading clinical trials...
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors
Conditions
Interventions
EZN-2968
Locations
1
United States
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Start Date
April 29, 2010
Completion Date
September 24, 2013
Last Updated
July 5, 2018
NCT07159659
NCT07169851
NCT07213804
NCT00026884
NCT07481851
NCT07191730
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions